Latest & greatest articles for tuberculosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tuberculosis

181. Treatment of Tuberculosis. (Abstract)

Treatment of Tuberculosis. 26605929 2015 12 04 2016 11 26 1533-4406 373 22 2015 Nov 26 The New England journal of medicine N. Engl. J. Med. Treatment of Tuberculosis. 2149-60 10.1056/NEJMra1413919 Horsburgh C Robert CR Jr Barry Clifton E CE 3rd Lange Christoph C eng Journal Article Review United States N Engl J Med 0255562 0028-4793 0 Antitubercular Agents AIM IM Adult Antitubercular Agents pharmacokinetics therapeutic use Child Humans Lung diagnostic imaging Mycobacterium tuberculosis (...) physiology Tomography, X-Ray Computed Tuberculosis diagnostic imaging drug therapy 2015 11 26 6 0 2015 11 26 6 0 2015 12 15 6 0 ppublish 26605929 10.1056/NEJMra1413919

2015 NEJM

182. Data for action: collection and use of local data to end tuberculosis. Full Text available with Trip Pro

Data for action: collection and use of local data to end tuberculosis. Accelerating progress in the fight against tuberculosis will require a drastic shift from a strategy focused on control to one focused on elimination. Successful disease elimination campaigns are characterised by locally tailored responses that are informed by appropriate data. To develop such a response to tuberculosis, we suggest a three-step process that includes improved collection and use of existing programmatic data (...) , collection of additional data (eg, geographic information, drug resistance, and risk factors) to inform tailored responses, and targeted collection of novel data (eg, sequencing data, targeted surveys, and contact investigations) to improve understanding of tuberculosis transmission dynamics. Development of a locally targeted response for tuberculosis will require substantial investment to reconfigure existing systems, coupled with additional empirical data to evaluate the effectiveness of specific

2015 Lancet

183. Stopping tuberculosis: a biosocial model for sustainable development. Full Text available with Trip Pro

Stopping tuberculosis: a biosocial model for sustainable development. Tuberculosis transmission and progression are largely driven by social factors such as poor living conditions and poor nutrition. Increased standards of living and social approaches helped to decrease the burden of tuberculosis before the introduction of chemotherapy in the 1940s. Since then, management of tuberculosis has been largely biomedical. More funding for tuberculosis since 2000, coinciding with the Millennium (...) Development Goals, has yielded progress in tuberculosis mortality but smaller reductions in incidence, which continues to pose a risk to sustainable development, especially in poor and susceptible populations. These at-risk populations need accelerated progress to end tuberculosis as resolved by the World Health Assembly in 2015. Effectively addressing the worldwide tuberculosis burden will need not only enhancement of biomedical approaches but also rebuilding of the social approaches of the past

2015 Lancet

184. Latent Mycobacterium tuberculosis Infection. (Abstract)

Latent Mycobacterium tuberculosis Infection. 26376149 2015 09 17 2018 12 02 1533-4406 373 12 2015 09 17 The New England journal of medicine N. Engl. J. Med. Latent Mycobacterium tuberculosis Infection. 1179-80 10.1056/NEJMc1508223 Getahun Haileyesus H Chaisson Richard E RE Raviglione Mario M eng P30 AI094189 AI NIAID NIH HHS United States Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antitubercular Agents V83O1VOZ8L Isoniazid AIM IM N Engl J Med. 2015 May 28;372(22):2127-35 (...) 26017823 N Engl J Med. 2015 Sep 17;373(12):1178 26376150 N Engl J Med. 2015 Sep 17;373(12):1178 26376151 N Engl J Med. 2015 Sep 17;373(12):1178-9 26376152 N Engl J Med. 2015 Sep 17;373(12):1179 26376153 Antitubercular Agents administration & dosage Humans Isoniazid administration & dosage Latent Tuberculosis Mycobacterium tuberculosis 2015 9 17 6 0 2015 9 17 6 0 2015 9 18 6 0 ppublish 26376149 10.1056/NEJMc1508223 10.1056/NEJMc1508223#SA5

2015 NEJM

185. Latent Mycobacterium tuberculosis Infection. Full Text available with Trip Pro

Latent Mycobacterium tuberculosis Infection. 26376150 2015 09 17 2018 12 02 1533-4406 373 12 2015 09 17 The New England journal of medicine N. Engl. J. Med. Latent Mycobacterium tuberculosis Infection. 1178 10.1056/NEJMc1508223 Jones Jeffrey G JG King Thomas C TC eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antitubercular Agents V83O1VOZ8L Isoniazid AIM IM N Engl J Med. 2015 May 28;372(22):2127-35 26017823 N Engl J Med. 2015 Sep 17;373(12):1179-80 26376149 Antitubercular (...) Agents administration & dosage Humans Isoniazid administration & dosage Latent Tuberculosis Mycobacterium tuberculosis 2015 9 17 6 0 2015 9 17 6 0 2015 9 18 6 0 ppublish 26376150 10.1056/NEJMc1508223 10.1056/NEJMc1508223#SA1

2015 NEJM

186. Latent Mycobacterium tuberculosis Infection. Full Text available with Trip Pro

Latent Mycobacterium tuberculosis Infection. 26376151 2015 09 17 2018 12 02 1533-4406 373 12 2015 09 17 The New England journal of medicine N. Engl. J. Med. Latent Mycobacterium tuberculosis Infection. 1178 10.1056/NEJMc1508223 Ogbuagu Onyema O Ogbuagu Arit A eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antitubercular Agents V83O1VOZ8L Isoniazid AIM IM N Engl J Med. 2015 May 28;372(22):2127-35 26017823 N Engl J Med. 2015 Sep 17;373(12):1179-80 26376149 Antitubercular Agents (...) administration & dosage Humans Isoniazid administration & dosage Latent Tuberculosis Mycobacterium tuberculosis 2015 9 17 6 0 2015 9 17 6 0 2015 9 18 6 0 ppublish 26376151 10.1056/NEJMc1508223 10.1056/NEJMc1508223#SA2

2015 NEJM

187. Latent Mycobacterium tuberculosis Infection. Full Text available with Trip Pro

Latent Mycobacterium tuberculosis Infection. 26376152 2015 09 17 2018 12 02 1533-4406 373 12 2015 09 17 The New England journal of medicine N. Engl. J. Med. Latent Mycobacterium tuberculosis Infection. 1178-9 10.1056/NEJMc1508223 Tam John K C JK eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antitubercular Agents V83O1VOZ8L Isoniazid AIM IM N Engl J Med. 2015 May 28;372(22):2127-35 26017823 N Engl J Med. 2015 Sep 17;373(12):1179-80 26376149 Antitubercular Agents (...) administration & dosage Humans Isoniazid administration & dosage Latent Tuberculosis Mycobacterium tuberculosis 2015 9 17 6 0 2015 9 17 6 0 2015 9 18 6 0 ppublish 26376152 10.1056/NEJMc1508223 10.1056/NEJMc1508223#SA3

2015 NEJM

188. Latent Mycobacterium tuberculosis Infection. Full Text available with Trip Pro

Latent Mycobacterium tuberculosis Infection. 26376153 2015 09 17 2018 12 02 1533-4406 373 12 2015 09 17 The New England journal of medicine N. Engl. J. Med. Latent Mycobacterium tuberculosis Infection. 1179 10.1056/NEJMc1508223 Flood Jennifer J Scott James J Belknap Robert R eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antitubercular Agents V83O1VOZ8L Isoniazid AIM IM N Engl J Med. 2015 May 28;372(22):2127-35 26017823 N Engl J Med. 2015 Sep 17;373(12):1179-80 26376149 (...) Antitubercular Agents administration & dosage Humans Isoniazid administration & dosage Latent Tuberculosis Mycobacterium tuberculosis 2015 9 17 6 0 2015 9 17 6 0 2015 9 18 6 0 ppublish 26376153 10.1056/NEJMc1508223 10.1056/NEJMc1508223#SA4

2015 NEJM

189. Diagnostic Challenges in Latent Tuberculosis Infection: A Brief Review of Available Tests and their Appropriate Use

Diagnostic Challenges in Latent Tuberculosis Infection: A Brief Review of Available Tests and their Appropriate Use Diagnostic Challenges in Latent Tuberculosis Infection: A Brief Review of Available Tests and their Appropriate Use – Clinical Correlations Search Diagnostic Challenges in Latent Tuberculosis Infection: A Brief Review of Available Tests and their Appropriate Use July 15, 2015 14 min read By: Miguel A. Saldivar, MD Peer Reviewed “Indeterminate.” Many clinicians have expressed (...) frustration when reading this word on a Quantiferon-TB Gold test result. The obligate follow-up question is: what is the next best step? Repeat the Quantiferon? Ignore it altogether and perform a Tuberculin Skin Test (TST) instead? Even worse, what happens when both tests are performed with discordant results? In order to answer some of these questions, this article begins with a very brief overview of Mycobacterium tuberculosis (TB) infection epidemiology. This is followed by a review of the tools

2015 Clinical Correlations

190. Bedaquiline (Sirturo) - pulmonary multidrug resistant tuberculosis

Bedaquiline (Sirturo) - pulmonary multidrug resistant tuberculosis Final Appraisal Recommendation Advice No: 0815 – March 2015 Bedaquiline (Sirturo ® ? ) 100 mg tablets Submission by Janssen-Cilag Ltd Additional note(s): ? AWMSG considered that bedaquiline (Sirturo ® ? ) satisfies the AWMSG criteria for ultra-orphan drug status. In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1334), which includes (...) Recommendation of AWMSG Bedaquiline (Sirturo ® ? ) is recommended as an option for use within NHS Wales for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group. Final

2015 All Wales Medicines Strategy Group

191. Guidelines on the management of latent tuberculosis infection

Guidelines on the management of latent tuberculosis infection Guidelines on the management of latent tuberculosis infection© World Health Organization 2015 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce (...) Data Guidelines on the management of latent tuberculosis infection. 1.Latent Tuberculosis. 2.Immunologic T ests. 3.Mycobacterium Tuberculosis – immunology. 4.Antitubercular Agents. 5.Guideline. I.World Health Organization. ISBN 978 92 4 154890 8 (NLM classification: WF 200)Guidelines on the management of latent tuberculosis infection1 Guidelines on the management of latent tuberculosis infection Contents Acknowledgements 2 Abbreviations 5 Declaration and management of conflict of interest 6

2015 World Health Organisation Guidelines

192. Global Tuberculosis Control: Toward the 2015 Targets and Beyond. Full Text available with Trip Pro

Global Tuberculosis Control: Toward the 2015 Targets and Beyond. Since 1990, progress has been made toward global tuberculosis (TB) control, as measured by targets set for 2015. However, TB remains a major threat to health around the world. In 2013, there were an estimated 11 million prevalent cases, and an estimated 9.0 million incident cases occurred globally. Approximately 1.5 million deaths were caused by TB, including 360,000 among people living with HIV. Substantial challenges threaten

2015 Annals of Internal Medicine

193. Effect of a culture-based screening algorithm on tuberculosis incidence in immigrants and refugees bound for the United States: a population-based cross-sectional study. Full Text available with Trip Pro

Effect of a culture-based screening algorithm on tuberculosis incidence in immigrants and refugees bound for the United States: a population-based cross-sectional study. Before 2007, immigrants and refugees bound for the United States were screened for tuberculosis (TB) by a smear-based algorithm that could not diagnose smear-negative/culture-positive TB. In 2007, the Centers for Disease Control and Prevention implemented a culture-based algorithm.To evaluate the effect of the culture-based

2015 Annals of Internal Medicine

194. Drug-resistance mechanisms and tuberculosis drugs Full Text available with Trip Pro

Drug-resistance mechanisms and tuberculosis drugs 25706840 2015 03 03 2018 11 13 1474-547X 385 9965 2015 Jan 24 Lancet (London, England) Lancet Drug-resistance mechanisms and tuberculosis drugs. 305-7 10.1016/S0140-6736(14)62450-8 S0140-6736(14)62450-8 Köser Claudio U CU Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge CB2 0QW, UK. Electronic address: cuk21@cam.ac.uk. Javid Babak B Department of Medicine, Addenbrooke's Hospital, University of Cambridge (...) Nicholas M NM Clinical Microbiology and Public Health Laboratory, Public Health England, Cambridge, UK. Burman William J WJ Denver Public Health, Denver, USA. Abubakar Ibrahim I Tuberculosis Section, Centre for Infectious Disease Surveillance and Control, Public Health England, London, UK; Research Department of Infection and Population Health, University College London, London, UK. Ismail Nazir A NA Centre for Tuberculosis, National Institute for Communicable Diseases, Johannesburg, South Africa

2015 Lancet

195. Systematic review with meta analysis: Directly observed treatment is not the only solution for poor adherence and low cure of tuberculosis

Systematic review with meta analysis: Directly observed treatment is not the only solution for poor adherence and low cure of tuberculosis Directly observed treatment is not the only solution for poor adherence and low cure of tuberculosis | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Directly observed treatment is not the only solution for poor adherence and low cure of tuberculosis Article Text Therapeutics/Prevention Systematic

2015 Evidence-Based Medicine

196. Randomised controlled trial: Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment

Randomised controlled trial: Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment Article Text Therapeutics/Prevention Randomised

2015 Evidence-Based Medicine

197. Tuberculosis (TB): care of the child and protection of staff and patients

Tuberculosis (TB): care of the child and protection of staff and patients Tuberculosis (TB): care of the child and protection of staff and patients | Great Ormond Street Hospital Google Tag Manager Navigation Search Search You are here Tuberculosis (TB): care of the child and protection of staff and patients Tuberculosis (TB): care of the child and protection of staff and patients Please note: that the NICE Guidance is in the process of being updated and this is expected to be published (...) in October 2015. Update of Clinical Guideline 117 Tuberculosis- clinical diagnosis, and measures for its prevention and control, incorporating PH37 Tuberculosis - Hard to reach Groups. Topics included Diagnostic procedures, Infectious diseases, Mental health/ behavioural conditions, Public health and, Respiratory. M.TB is usually caused by an organism in the mycobacterium tuberculosis complex, usually mycobacterium tuberculosis (M.TB) or mycobacterium Bovis (M. Bovis). M.TB will now be referred to as TB

2015 Publication 1593

198. [Interferon-gamma release assays as in vitro screening tests for latent tuberculosis infection]

[Interferon-gamma release assays as in vitro screening tests for latent tuberculosis infection] Tests in vitro de dépistage de l'infection tuberculeuse latente par détection de production d'interféron gamma [Interferon-gamma release assays as in vitro screening tests for latent tuberculosis infection] Tests in vitro de dépistage de l'infection tuberculeuse latente par détection de production d'interféron gamma [Interferon-gamma release assays as in vitro screening tests for latent tuberculosis (...) infection] Haute Autorité de Santé Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Haute Autorité de Santé. Tests in vitro de dépistage de l'infection tuberculeuse latente par détection de production d'interféron gamma. [Interferon-gamma release assays as in vitro screening tests for latent tuberculosis infection] Paris: Haute Autorité de Santé

2015 Health Technology Assessment (HTA) Database.

199. Expert Opinion on the introduction of new drugs for tuberculosis control in the EU/EEA

Expert Opinion on the introduction of new drugs for tuberculosis control in the EU/EEA SCIENTIFIC ADVICE Expert Opinion on the introduction of new drugs for tuberculosis control in the EU/EEA www.ecdc.europa.eu ECDC SCIENTIFIC ADVICE Expert Opinion on the introduction of new drugs for tuberculosis control in the EU/EEA ii This report was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Andreas Sandgren and produced by an ECDC editorial team (...) citation: European Centre for Disease Prevention and Control. Expert Opinion on the introduction of new drugs for tuberculosis control in the EU/EEA. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-626-7 doi 10.2900/113100 Catalogue number TQ-01-15-150-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged SCIENTIFIC ADVICE Expert Opinion on the introduction of new drugs for tuberculosis control in the EU/EEA iii

2015 European Centre for Disease Prevention and Control - Expert Opinion

200. ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update

ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update Options

2015 European Respiratory Society